GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » EV-to-Revenue

Nicox (NICXF) EV-to-Revenue : 3.84 (As of May. 01, 2024)


View and export this data going back to . Start your Free Trial

What is Nicox EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nicox's enterprise value is $23.42 Mil. Nicox's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $6.10 Mil. Therefore, Nicox's EV-to-Revenue for today is 3.84.

The historical rank and industry rank for Nicox's EV-to-Revenue or its related term are showing as below:

NICXF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.46   Med: 14.27   Max: 17406.56
Current: 3.68

During the past 13 years, the highest EV-to-Revenue of Nicox was 17406.56. The lowest was 1.46. And the median was 14.27.

NICXF's EV-to-Revenue is ranked better than
66.34% of 1031 companies
in the Biotechnology industry
Industry Median: 7.91 vs NICXF: 3.68

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), Nicox's stock price is $0.44. Nicox's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.12. Therefore, Nicox's PS Ratio for today is 3.61.


Nicox EV-to-Revenue Historical Data

The historical data trend for Nicox's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox EV-to-Revenue Chart

Nicox Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.91 15.67 9.22 10.46 9.48

Nicox Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.46 - 9.48 -

Competitive Comparison of Nicox's EV-to-Revenue

For the Biotechnology subindustry, Nicox's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nicox's EV-to-Revenue falls into.



Nicox EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nicox's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=23.424/6.096
=3.84

Nicox's current Enterprise Value is $23.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nicox's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $6.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox  (OTCPK:NICXF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nicox's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.44/0.122
=3.61

Nicox's share price for today is $0.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $0.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nicox's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox (NICXF) Business Description

Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines